Digital primary care company Curai Health scored $27.5 million in Series B funding from Morningside Ventures, as well as returning backers General Catalyst and Khosla Ventures. The company, which was founded by Neal Khosla and Xavier Amatriain, runs on a subscription-based model.
Users can pay $7.99 a month for the subscription and then access telemedicine visits with doctors. The service also lets patients set goals around things such as weight management and sleep.
The company plans to use the money to expand its efforts and scale.
“Primary care should be just that -- primary -- to every single person, but without drastic innovation, the current system will only create more scarcity, higher costs and a sicker population,” Khosla said in a statement.
“AI has the power to scale the care provided by a finite number of physicians so that it can meet the demands of a global population. We’ve dedicated countless hours to in-depth clinical and technical R&D to ensure our system gets smarter, more efficient and increasingly cost-effective after every patient encounter. We aren’t interested in the 10% to 20% cost savings that most virtual care platforms aspire to deliver. We’re working toward 10 and, eventually 100x, care-delivery cost reductions.”
This morning, digital health startup Ōmcare announced a $2.5 million investment led by Connect the Grey Investment Management.
The Minnesota-based company works on the medication adherence space. It created a tool called Ōmcare Home Health Hub, which is a pill dispenser that also allows for two-way videos and three-way calling. The medications are locked and the tool can track when the medication is dispensed. The tool allows for multi-dose packing.
The money will be put towards commercializing the product, which is due to launch in 2021.
"We are extending the reach of caregivers into the home," Lisa Lavin, Ōmcare founder and CEO, said in a statement. "Taking the right medication at the right time can be life-changing and can enable people to live more independent, vibrant lives. This is about having more life options and making it easier for caregivers to care."
Virtual substance use disorder care provider Workit Health announced a $12 million Series B investment led by FirstMark Capital. Lux Capital, GingerBread Capital, Blue Cross and Blue Shield Venture Partners and actor Rob Lowe also participated in the raise.
The app-based platform connects patients to addiction medications like buprenorphine and naltrexone, as well as telemedicine therapy with a live provider. The company did not outline specific plans for the new funds outside of general expansion.
“The demand for telemedicine care accelerated with COVID-19, but providing quality addiction treatment to people in the privacy of their home has been our priority at Workit Health since day one,” Robin McIntosh, Workit Health’s cofounder and co-CEO, said in a statement. “With Workit Health, it’s easier than ever before to take the first step towards recovery, and we’re excited to use this round of funding to bring our holistic and evidence-based care to more Americans.”
Lucine, a French startup offering a digital therapeutic for chronic pain, has raised $6.6 million (€5.5 million) in new funds from Kurma Partners, Bpifrance's Autonomous Patient Fund, BNP Paribas Développement, Aquiti Gestion and Irdi Soridec.
The company's app uses face recognition and AI to quantify the user's pain and deliver personalized treatments such as cognitive behavioral therapy. With the new money, Lucine said it will be putting together new clinical studies for its product.
"The digital therapy developed by Lucine to relieve patients suffering from chronic pain is an original alternative to conventional drug treatments," Chahra Louafi, director of the biotech and ecotech investment division of Bpifrance, said in a statement. "We are delighted to support them in their development ambitions."
